Opthea Ltd at Jefferies Healthcare Conference Transcript
(audio in progress) Jefferies Australia healthcare research team. And it's my absolute pleasure to be hosting this presentation from Megan Baldwin, CEO of Opthea. So Megan, thanks very much for joining, and over to you for the presentation.
Thanks very much, David, and good afternoon, everyone. And thanks to the Jefferies team for the opportunity to tell you a little bit more about Opthea and our program to develop OPT-302, which is a biologic inhibitor of novel members of the VEGF family of molecules that have a very important role in the progression of wet age-related macular degeneration.
So wet AMD is the leading cause of blindness in people over the age of 50 around the world. It impacts about 3.5 million people in the United States and Europe alone. And it's generally treated with a class of therapies called the VEGF-A inhibitors, which generate revenues selectively for wet AMD in excess of $8 billion per annum.
OPT-302 and Opthea has the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
